


# INVESTOR NEWS



April 2023




## STRONG PROGRESS THROUGH STEADY AND EFFICIENT EXECUTION (Annual Report 2022)

2cureX released the Annual report for 2022 on 20. April 2023. Read it [here](#).

In the Annual Report, you can for example read about:

- Follow-up on our 2022 and 2023 goals
- Our successful execution of the commercial strategy builds unique sales pipeline
- How 3D Microtumor technologies are gaining tremendous momentum
- IVD-Regulation gives 2cureX a competitive edge
- How automation of IndiTreat® reaches an important milestone
- Our Results and Financial Position



## CEO BLOG: THE THREAT OF THE NEW IVD REGULATION – OR IS IT AN OPPORTUNITY?

“17% of today’s [IVD] devices will be discontinued – in most cases due to the cost of CE-marking under IVD Regulation” and “54% of SMEs [might] not be able to certify their tests”. This is the sinister picture that Medtech Europe, the European industry association of manufacturers and distributors, paints in their recently released “Transition to the IVD Regulation - MedTech Europe Survey Results for October 2022” report.

That’s more than 7,000 devices that will be discontinued – decision already made by their manufacturers – because their margins can’t compensate the additional regulatory compliance costs, and hundreds of companies at risk of having to withdraw their products from the market due to not matching the timelines for the transition to IVD-R. Talk about an industry shakeup.

Read the full Blog [here](#)



**CEO Fernando Andreu**

## Upcoming events in Q2 2023:

20. April 2023 - Company presentation to “2cureX AB – Venner/Vänner” (link to [Facebook Group](#))

20. April 2023 – CEO Blog: IVD-R and 2cureX Newsletter

25. May 2023 – Annual General Meeting

25. May 2023 – Release of Q1 2023 report

25. May 2023 – Q1 2023 live commentary at Infront Direkt Studios

28. June 2023 – 2cureX presentation at ESMO World Congress on Gastrointestinal cancer (link to [ESMO GI](#))

## Contact

### ADDRESS

2cureX  
Fruebjergvej 3,  
2100 Copenhagen,  
Denmark

### E-MAIL (INVESTORS)

[ir@2curex.com](mailto:ir@2curex.com)

### E-MAIL (OTHER QUESTIONS)

[info@2curex.com](mailto:info@2curex.com)

